A computationally efficient reduced order model to generate multi-parameter fluid-thermal databases

A reduced order model (ROM) is proposed to generate multi-parameter databases of some fluid-thermal problems, using a combination of proper orthogonal decomposition, a gradient-like method, and a continuation method. The resulting ROM greatly reduces the CPU time required by slower methods based on genetic algorithm formulations. As a byproduct, the number of required snapshots is also reduced, which yields an additional improvement of the computational efficiency. The work presented in this article aims to facilitate the use of ROMs in industrial environments, in which time is a very important asset. The methodology is illustrated with the non-isothermal flow past a backward-facing step in the laminar regime, which is a representative problem, related to the engineering design of micro-heat sinks

Crystal Structure of the Sodium Cobaltate Deuterate Superconductor NaxCoO2o4xD2O (x=1/3)

Neutron and x-ray powder diffraction have been used to investigate the crystal structures of a sample of the newly-discovered superconducting sodium cobaltate deuterate compound with composition Na0.31(3)CoO2o1.25(2)D2O and its anhydrous parent compound Na0.61(1)CoO2. The deuterate superconducting compound is formed by coordinating four D2O molecules (two above and two below) to each Na ion in a way that gives Na-O distances nearly equal to those in the parent compound. One deuteron of the D2O molecule is hydrogen bonded to an oxygen atom in the CoO2 plane and the oxygen atom and the second deuteron of each D2O molecule lie approximately in a plane between the Na layer and the CoO2 layers. This coordination of Na by four D2O molecules leads to ordering of the Na ions and D2O molecules. The sample studied here, which has Tc=4.5 K, has a refined composition of Na0.31(3)CoO2o1.25(2)D2O, in agreement with the expected 1:4 ratio of Na to D2O. These results show that the optimal superconducting composition should be viewed as a specific hydrated compound, not a solid solution of Na and D2O (H2O) in NaxCoO2oyD2O. Studies of physical properties vs. Na or D2O composition should be viewed with caution until it is verified that the compound remains in the same phase over the composition range of the study.Comment: 22 pages, 8 figure

Sweet Sorghum: Genetics, Breeding and Commercialization

This chapter describes sweet sorghum characteristics and utilization as food and fuel; climate requirements and distribution; reproductive biology including floral biology, pollination, fertilization and seed development; genomics; genetic transformation; breeding objectives and methods; and commercialization. Full exploration of the available genetic resources through plant breeding with the aid of molecular tools could dramatically increase biomass yield of sorghum and thus meet the demand of feedstocks for biofuel production without a significant impact on our food supply and natural environment

Energy Sorghum : An alternative energy crop A Handbook

Increasing world market prices for fossil fuels, driven by limited reserves, growing demand and instability in producing regions, now render renewable fuels economical. Such fuels are also a pathway to reducing greenhouse gas (GHG) emissions and mitigating climate change. The transport sector which is almost totally dependent on fossil fuels, particularly for powering personal vehicles and trucks, is the most concerned sector. Biofuels, defined as solid, liquid or gas fuels derived from biomass, are today the only direct substitute for fossil fuels on a significant scale particularly in transport sector. Biofuels are considered environmentally friendly because the CO2 emissions they produce during combustion is balanced by the CO2 absorbed by the plants growth. To be a viable substitute for fossil fuels, an alternative fuel should not only have superior environmental benefits over the fossil fuels it substitutes, be economically competitive with it, and be available in sufficient quantities to make meaningful impact on energy demand, but it should also provide a net energy gain over the energy invested to produce it and have minimal effect on food security... {This handbook was elaborated in the framework of the SWEETFUEL project (grant agreement number 227422), supported by the European Commission

Animal Botulism Outcomes in the AniBioThreat Project

Botulism disease in both humans and animals is a worldwide concern. Botulinum neurotoxins produced by Clostridium botulinum and other Clostridium species are the most potent biological substances known and are responsible for flaccid paralysis leading to a high mortality rate. Clostridium botulinum and botulinum neurotoxins are considered potential weapons for bioterrorism and have been included in the Australia Group List of Biological Agents. In 2010 the European Commission (DG Justice, Freedom and Security) funded a 3-year project named AniBioThreat to improve the EU's capacity to counter animal bioterrorism threats. A detection portfolio with screening methods for botulism agents and incidents was needed to improve tracking and tracing of accidental and deliberate contamination of the feed and food chain with botulinum neurotoxins and other Clostridia. The complexity of this threat required acquiring new genetic information to better understand the diversity of these Clostridia and develop detection methods targeting both highly specific genetic markers of these Clostridia and the neurotoxins they are able to produce. Several European institutes participating in the AniBioThreat project collaborated on this program to achieve these objectives. Their scientific developments are discussed here

Recovery of dialysis patients with COVID-19 : health outcomes 3 months after diagnosis in ERACODA

Background. Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods. We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results. In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8-6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions. Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials

BACKGROUND: In a previous report, we hypothesized that responses to placebo were high in child and adolescent depression because of specific psychopathological factors associated with youth major depression. The purpose of this study was to compare the placebo response rates in pharmacological trials for major depressive disorder (MDD), obsessive compulsive disorder (OCD) and other anxiety disorders (AD-non-OCD). METHODOLOGY AND PRINCIPAL FINDINGS: We reviewed the literature relevant to the use of psychotropic medication in children and adolescents with internalized disorders, restricting our review to double-blind studies including a placebo arm. Placebo response rates were pooled and compared according to diagnosis (MDD vs. OCD vs. AD-non-OCD), age (adolescent vs. child), and date of publication. From 1972 to 2007, we found 23 trials that evaluated the efficacy of psychotropic medication (mainly non-tricyclic antidepressants) involving youth with MDD, 7 pertaining to youth with OCD, and 10 pertaining to youth with other anxiety disorders (N = 2533 patients in placebo arms). As hypothesized, the placebo response rate was significantly higher in studies on MDD, than in those examining OCD and AD-non-OCD (49.6% [range: 17-90%] vs. 31% [range: 4-41%] vs. 39.6% [range: 9-53], respectively, ANOVA F = 7.1, p = 0.002). Children showed a higher stable placebo response within all three diagnoses than adolescents, though this difference was not significant. Finally, no significant effects were found with respect to the year of publication. CONCLUSION: MDD in children and adolescents appears to be more responsive to placebo than other internalized conditions, which highlights differential psychopathology